FDA finds data integrity problems in recent warning letters
Regulatory NewsJoanne S. Eglovitch
APIsCDERCompoundingGMPManufacturingOTCOver the counter drugs (OTCs)PharmaceuticalsQuality Assurance and ControlRegulatory Intelligence/PolicyUnited StatesWarning letters